Table 2.
Selected Clinicopathologic Features of Vaginal and Vulvar Smooth Muscle Tumors.
| Vaginal Spindled Leiomyoma (N=39) | Vaginal Mitotically Active Leiomyoma (N=1) | Vaginal Leiomyoma with Bizarre Nuclei (N=1) | Vaginal Spindled Leiomyosarcoma (N=11) | Vaginal Myxoid Leiomyosarcoma (N=1) | Vulvar Spindled Leiomyoma (N=13) | Vulvar STUMP (N=2) | Vulvar Spindled Leiomyosarcoma (N=3) | |
|---|---|---|---|---|---|---|---|---|
| Age | ||||||||
| Mean (SD) | 50 (13) | 71 | 36 | 53.5 (21.8) | 67 | 51.8 (16.1) | 45, 50 | 56, 68, 72 |
| Range | (22–87) | (15–78) | (28–77) | |||||
| Tumor Size (cm, greatest dimension) | ||||||||
| N | 39 | 1 | 1 | 11 | 1 | 12 | 2 | 3 |
| Mean (SD) | 2.6 (1.5) | 0.5 | 4.5 | 5.9 (1.6) | 4 | 4 (2.9) | 6, 8.5 | 5.5, 11, 13.5 |
| Range | (0.6–7) | (3.5–9) | (0.5–11.2) | |||||
| Degree of Atypia* | ||||||||
| Mild to moderate | 39 (100%) | 1 (100%) | 0 (0%) | 1 (9.1%) | 0 (0%) | 13 (100%) | 0 (0%) | 0 (0%) |
| Moderate to severe | 0 (0%) | 0 (0%) | 1 (100%) | 10 (90.9%) | 1 (100%) | 0 (0%) | 2 (100%) | 3 (100%) |
| Mitotic Index (per 10 HPFs)* | ||||||||
| Median | 0 | 10 | 0 | 15 | 6 | 0 | 1, 1 | 8, 34, 23 |
| Q1, Q3 | 0, 0 | 11, 23 | 0, 1 | |||||
| Range | (0–7) | (5–32) | (0–1) | |||||
| Atypical Mitotic Figures | ||||||||
| Mitotic index of zero | 32 (82.1%) | 0 (0%) | 1 (100%) | 0 (0%) | 0 (0%) | 7 (53.8%) | 0 (0%) | 0 (0%) |
| N | 7 (17.9%) | 1 (100%) | 0 (0%) | 0 (0%) | 0 (0%) | 6 (46.2%) | 2 (100%) | 1 (33.3%) |
| Y | 0 (0%) | 0 (0%) | 0 (0%) | 11 (100%) | 1 (100%) | 0 (0%) | 0 (0%) | 2 (66.7%) |
| Tumor Cell Necrosis* | ||||||||
| N | 39 (100%) | 1 (100%) | 1 (100%) | 4 (36.4%) | 0 (0%) | 13 (100%) | 2 (100%) | 0 (0%) |
| Y | 0 (0%) | 0 (0%) | 0 (0%) | 7 (63.6%) | 1 (100%) | 0 (0%) | 0 (0%) | 3 (100%) |
| Ischemic Necrosis | ||||||||
| N | 35 (89.7%) | 1 (100%) | 1 (100%) | 5 (45.5%) | 0 (0%) | 11 (84.6%) | 2 (100%) | 0 (0%) |
| Y | 4 (10.3%) | 0 (0%) | 0 (0%) | 6 (54.5%) | 1 (100%) | 2 (15.4%) | 0 (0%) | 3 (100%) |
| Tumor Interface | ||||||||
| Circumscribed | 22 (56.4%) | 0 (0%) | 0 (0%) | 4 (36.4%) | 0 (0%) | 8 (61.5%) | 1 (50%) | 0 (0%) |
| Infiltrative | 4 (10.3%) | 0 (0%) | 0 (0%) | 5 (45.5%) | 1 (100%) | 3 (23.1%) | 1 (50%) | 3 (100%) |
| UNK | 13 (33.3%) | 1 (100%) | 1 (100%) | 2 (18.2%) | 0 (0%) | 2 (15.4%) | 0 (0%) | 0 (0%) |
| Margin Status | ||||||||
| Negative | 7 (17.9%) | 0 (0%) | 0 (0%) | 6 (54.5%) | 1 (100%) | 3 (30.8%) | 2 (100%) | 1 (33.3%) |
| Positive | 32 (82.1%) | 1 (100%) | 1 (100%) | 3 (45.5%) | 0 (0%) | 9 (69.2%) | 0 (0%) | 2 (66.7%) |
| Follow Up (months) | ||||||||
| N | 35 | 1 | 1 | 11 | 1 | 9 | 2 | 3 |
| Median | 85 | 15 | 180 | 64 | 150 | 12 | 9, 19 | 4, 36, 56 |
| Range | (1–226) | (2–234) | (1–137) | |||||
| Any Recurrence | 0 | 0 | 0 | 8 | 1 | 0 | 0 | 3 |
*
Includes only feature assessment of pre-neoadjuvant therapy tumors
STUMP (smooth muscle tumor of uncertain malignant potential); HPFs (high power fields); UNK (unknown)